In terms of safety, most of the manifestations were grade 1-2 AEs, including nausea, vomiting, fatigue, rash and acnes, paronychia, elevated ALT/AST, and there were four cases (12.9%) of grade 3 AEs (including two cases of leukopenia, one case of diarrhea, and one case of interstitial pneumonitis), which were mainly related to high doses of the targeted drug. This evidence concerns the gene GPT and Decreased total leukocyte count.